WEDNESDAY, Aug. 20, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a serious form of fatty liver disease. The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderateContinue Reading

THURSDAY, July 24, 2025 (HealthDay News) — Heavy-drinking Americans are more than twice as likely to develop alcohol-related liver disease compared to two decades ago, even though folks generally imbibe the same amount as before, a new study says. This is likely because heavy alcohol use has increased among groupsContinue Reading

FRIDAY, June 6, 2025 (HealthDay News) — A repurposed diabetes drug can be an effective tool against fatty liver disease, a new clinical trial has found. Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which doctors call metabolic dysfunction-associated steatohepatitis,Continue Reading